- Home
- UGRO vs APVO Comparison
UGRO vs APVO Comparison
Compare UGRO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- APVO
- Stock Information
- Founded
- UGRO 2014
- APVO 2016
- Country
- UGRO United States
- APVO United States
- Employees
- UGRO N/A
- APVO N/A
- Industry
- UGRO Industrial Specialties
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- APVO Health Care
- Exchange
- UGRO Nasdaq
- APVO Nasdaq
- Market Cap
- UGRO 5.5M
- APVO 4.1M
- IPO Year
- UGRO N/A
- APVO N/A
- Fundamental
- Price
- UGRO $0.30
- APVO $3.23
- Analyst Decision
- UGRO Strong Buy
- APVO Strong Buy
- Analyst Count
- UGRO 1
- APVO 1
- Target Price
- UGRO $3.00
- APVO $5,920.00
- AVG Volume (30 Days)
- UGRO 457.6K
- APVO 6.7M
- Earning Date
- UGRO 07-07-2025
- APVO 08-07-2025
- Dividend Yield
- UGRO N/A
- APVO N/A
- EPS Growth
- UGRO N/A
- APVO N/A
- EPS
- UGRO N/A
- APVO N/A
- Revenue
- UGRO $59,985,138.00
- APVO N/A
- Revenue This Year
- UGRO N/A
- APVO N/A
- Revenue Next Year
- UGRO $31.25
- APVO N/A
- P/E Ratio
- UGRO N/A
- APVO N/A
- Revenue Growth
- UGRO N/A
- APVO N/A
- 52 Week Low
- UGRO $0.26
- APVO $2.81
- 52 Week High
- UGRO $1.92
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- UGRO 36.47
- APVO 34.28
- Support Level
- UGRO $0.29
- APVO $2.81
- Resistance Level
- UGRO $0.33
- APVO $13.11
- Average True Range (ATR)
- UGRO 0.04
- APVO 1.10
- MACD
- UGRO -0.00
- APVO 0.30
- Stochastic Oscillator
- UGRO 21.29
- APVO 4.08
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.